India to consider clinical trials data of two full doses of AstraZeneca vaccine

India will consider clinical trial data for the two full-dose Oxford-AstraZeneca Covid-19 vaccine candidate which the firm says has an efficacy of 62% and not the “half plus full” dose regime which is claimed to be up to 90% effective but has attracted criticism for dosing errors.